Pharma Stock Posts Strong FY25 Results, Stock Jumps Over 10% Amid Global Expansion Plans

The share price of Balaxi Pharmaceuticals on the NSE is currently Rs 48.68 as of 12:53 p.m. IST on Monday, August 11, according to the latest information available. This represents a gain of 11.47% from the closing price of the previous day. Since its opening price of Rs 49.00, the stock has fluctuated between an intraday low of Rs 47.10 and a high of Rs 52.00.

All this comes after impressive quarterly financial metrics. In the March quarter (Q4FY25), Balaxi netted Rs 76.27 crore in sales, marking a 27.5% YoY increase from Rs 59.83 Cr in Q4FY24 and a 61% increase in net profits to Rs 8.64 crores compared to Q3FY25. For the full year FY25, the company's revenue stood at Rs 293 crore, an increase of 22% from FY24's Rs 240 crore. More impressively, the company turned a net profit of Rs 25 crores in FY25, a jaw-dropping 1350% increase year-on-year compared to a net loss of Rs 2 crores in FY24.

In terms of future growth, Balaxi Pharmaceuticals is pursuing new markets and scaling operations. The company is intending to capture other Latin American countries, Southeast Asia and the CIS regions after successfully implementing the Honduras and El Salvador Model subsidiary into its business. Balaxi has also claimed to be investing in the backward integration of the supply chain for pharma formulation manufacturing, starting with a unit in Hyderabad. Construction is already underway and funded from a newly completed Rs 47.57 crore preferential issue to investors.

The upcoming Hyderabad facility will help Bolaaxi achieve its strategic goals of offering a balanced portfolio of branded and generic medicines to sustain optimized margins across primary geographies. With the acquisition in frontier markets, over the next five years, Balaxi aims to achieve deeper penetration in the existing market with diversified distribution channels and an expanded product portfolio.

Also, Balaxi's shareholding information indicates a striking change. In March, Ebisu Global Opportunities Fund Limited and Unico Global Opportunities Fund Limited bought 45.21 lakh and 45.77 lakh shares, respectively, at Rs 53 per share in bulk deals. At the same time, MGC Fund Limited and Elala India Opportunities Fund ceded their positions by equally distributing an identical volume of shares. According to the NSE, 65.99 % of the company is held by the promoter group, while the rest 34.01 % is in the hands of public shareholders.

Balaxi Pharmaceuticals is part of the IPR-based pharma companies, which concentrate on the manufacturing, warehousing and distribution of more than 610 registered trademarks and generic pharmaceutical products. Its portfolio comprises tablets, injectables, liquids and capsules manufactured by WHO-GMP accredited contract manufacturers in India, China and Portugal.